2021-11-04

Triastek is selected as one of the recipient of the 2021 AAPS Best Abstract Award

2021-10-27

Triastek Announced Opening Strategy of Era 2.0, Starting Global Business Cooperation

2021-10-14

A Double Blessing Has Descended upon the House!

2021-09-14

Breaking the new record of product development speed of emerging technologies, Triastek’s third in-house developed drug T21 submitted the PIND meeting request to the FDA

2021-07-14

Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE

2021-02-09

MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA